Metabolic Profiles during an Oral Glucose Tolerance Test in Pregnant Women with and without Gestational Diabetes

Abstract

Background/Aim: Gestational diabetes (GDM) is a complex metabolic condition associated with hyperpglycemia that is diagnosed in an oral glucose tolerance test (OGTT) during pregnancy. For a deeper understanding of the pathology of the disease, further investigations during pregnancy are required, ideally under metabolic challenging conditions.

Methods: We performed targeted metabolomics in a group of 24 well-matched women during an oral glucose tolerance test (OGTT). 231 plasma metabolites were profiled and compared to conventional clinical diagnostics.

Results: A pattern of 8 metabolites differed between GDM and healthy controls as early as 30 min in an OGTT (AUC 0.977±0.008), and an increase in acylcarnitine C18:0, decreased concentrations of diacyl phosphatidylcholines (PC aa) C34:4, PC aa C36:4, PC aa C38:5, Lyso PC C20:4 and arachidonic acid were associated with insulin resistance.

Conclusion: Our data suggest an additional value of metabolite pattern in the diagnosis of GDM and describe altered pathways that might be subjected to a more precise diagnosis and individualized therapy.

Key words

GDM - glucose tolerance test - pregnancy - targeted metabolomics - metabolites - insulin resistance

• References

• 1 Kleinwechter H, Schafer-Graf U, Buhrer C et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up care: Practice Guideline of the German Diabetes Association(DDG) and the German Association for Gynaecologyand Obstetrics (DGGG). Exp Clin Endocrinol Diabetes 2014; 122: 395-405
• 2 Manzoor N, Moses RG. Diagnosis of gestational diabetes mellitus: a different paradigm to consider. Diabetes Care 2013; 36: e187
• 3 Sacks DB. Diagnosis of gestational diabetes mellitus: it is time for international consensus. Clin Chem 2014; 60: 141-143
• 4 Catalano PM, McIntyre HD, Cruickshank JK et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012; 35: 780-786
• 5 Seghieri G, Tesi F, De Bellis A et al. Long term predictors of post-partum glucose metabolism in women with gestational diabetes mellitus. Exp Clin Endocrinol Diabetes 2010; 118: 485-489
• 6 Crete JE, Anasti JN. Diagnosis of gestational diabetes mellitus: can we avoid the glucose challenge test?. J Am Assoc Nurse Pract 2013; 25: 329-333
• 7 American Diabetes Association . Standards of Medical Care in Diabetes 2014. Diabetes Care 2014; 37: S14-S80
• 8 Xu Y, Jin B, Sun L et al. The expression of FoxO1 in placenta and omental adipose tissue of gestational diabetes mellitus. Exp Clin Endocrinol Diabetes 2014; 122: 287-294
• 9 Kim SY, England JL, Sharma JA et al. Gestational diabetes mellitus and risk of childhood overweight and obesity in offspring: a systematic review. Exp Diabetes Res 2011; 2011: 541308
• 10 Graca G, Duarte IF, Barros AS et al. Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res 2010; 9: 6016-6024
• 11 Diaz SO, Pinto J, Graca G et al. Metabolic biomarkers of prenatal disorders: an exploratory NMR metabonomics study of second trimester maternal urine and blood plasma. J Proteome Res 2011; 10: 3732-3742
• 12 Graca G, Goodfellow BJ, Barros AS et al. UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol Biosyst 2012; 8: 1243-1254
• 13 Sachse D, Baerug A, Sletner L et al. Urine NMR metabolomics analysis of breastfeeding biomarkers during and after pregnancy in a large prospective cohort study. Scand J Clin Lab Invest 2014; 74: 264-272
• 14 Dudzik D, Zorawski M, Skotnicki M et al. Metabolic fingerprint of Gestational Diabetes Mellitus. J Proteomics 2014; 103: 57-71
• 15 Scholtens DM, Muehlbauer MJ, Daya NR et al. Metabolomics reveals broad-scale metabolic perturbations in hyperglycemic mothers during pregnancy. Diabetes Care 2014; 37: 158-166
• 16 Prentice KJ, Luu L, Allister EM et al. The Metabolite CMPF Is Elevated in Diabetes and Induces beta Cell Dysfunction. Cell Metab 2014; 19: 653-666
• 17 Yin P, Peter A, Franken H et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 2013; 59: 833-845
• 18 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
• 19 Wang-Sattler R, Yu Z, Herder C et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012; 8: 615
• 20 Suhre K, Meisinger C, Doring A et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010; 5: e13953
• 21 Ferrannini E, Natali A, Camastra S et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013; 62: 1730-1737
• 22 Ramsay SL, Stoegg WM, Weinberger KM et al. Apparatus and method for analyzing a metabolite profile. [EP 1875401 A211] 2007; 1-67 Ref Type: Patent
• 23 R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. ISBN 3-900051-07-0 2008
• 24 Kim H, Golub GH, Park H. Missing value estimation for DNA microarray gene expression data: local least squares imputation. Bioinformatics 2005; 21: 187-198
• 25 Stacklies W, Redestig H, Scholz M et al. pcaMethods – a bioconductor package providing PCA methods for incomplete data. Bioinformatics 2007; 23: 1164-1167
• 26 Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3 -Art. 3
• 27 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 1995; 57: 289-300
• 28 Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 2010; 33: 1-22
• 29 Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77
• 30 Mai M, Tonjes A, Kovacs P et al. Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS ONE 2013; 8: e82459
• 31 Wurtz P, Makinen VP, Soininen P et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012; 61: 1372-1380
• 32 Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15: 606-614
• 33 Shah SH, Crosslin DR, Haynes CS et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 2012; 55: 321-330
• 34 Newgard CB, An J, Bain JR et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-326
• 35 Fiehn O, Garvey WT, Newman JW et al. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010; 5: e15234
• 36 Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453
• 37 Soga T, Ohishi T, Matsui T et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005; 326: 744-751
• 38 Metz SA. Ether-linked lysophospholipids initiate insulin secretion. Lysophospholipids may mediate effects of phospholipase A2 activation on hormone release. Diabetes 1986; 35: 808-817
• 39 Lin S, Yang Z, Liu H et al. Beyond glucose: metabolic shifts in responses to the effects of the oral glucose tolerance test and the high-fructose diet in rats. Mol Biosyst 2011; 7: 1537-1548
• 40 Zhao X, Fritsche J, Wang J et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 2010; 6: 362-374
• 41 Menni C, Fauman E, Erte I et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013; 62: 4270-4276
• 42 Bailey CJ, Aschner P, Del Prato S et al. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 2013; 10: 397-409